ALLOGENEIC RELATED DONOR STEM CELL TRANSPLANTATION IN AML CR1: ANY RISK FACTOR FOR BETTER SURVIVAL?

被引：0
|
作者：
Guvenc, S. [1 ]
Ozcelik, E. [2 ]
Hindilerden, F. [1 ]
Hasbal, N. [1 ]
Serefhanoglu, S. [2 ]
Kucukkaya, R. [1 ]
Arat, M. [1 ]
机构：
[1] Istanbul Bilim Univ, Hematol, Istanbul, Turkey
[2] Sisli Florence Nightingale Hosp, Hematol, Istanbul, Turkey
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P036
引用
收藏
页码：S117 / S118
页数：2
相关论文
共 50 条
  • [31] Donor Selection For Haploidentical Hematopoietic Stem Cell Transplantation: Who Is The Better - Donor-Recipient Risk Factor Analysis
    Wang, Yu
    Huang, Xiao Jun
    BLOOD, 2013, 122 (21)
  • [32] Donor-recipient RH incompatibility is a risk factor for mortality after pediatric matched related allogeneic hematopoietic stem cell transplantation
    Ghanem, K.
    Hariss, N.
    Merabi, Z.
    Kreidieh, N.
    Tarek, N.
    Saab, R.
    Muwakkit, S.
    El-Solh, H.
    Abboud, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S181 - S181
  • [33] Improved survival with adjuvant donor lymphocyte transfusions following allogeneic stem cell transplantation after reduced intensity conditioning for high-risk AML.
    Schleuning, Michael
    Schmid, Christoph
    Koenecke, Christian
    Hertenstein, Bemd
    Baurmann, Herrad
    Schwerdtfeger, Rainer
    Kolb, Hans-Jochem
    BLOOD, 2006, 108 (11) : 1046A - 1046A
  • [34] PATIENTS' PERSPECTIVES ON PSYCHOSOCIAL SUPPORT IN ALLOGENEIC STEM CELL TRANSPLANTATION WITH A RELATED DONOR
    Desacmps, Emma
    Kinds, Lotte
    De Wilde, Sofie
    Pape, Eva
    Quaghebeur, Marijke
    Kerre, Tessa
    BONE MARROW TRANSPLANTATION, 2024, 59 : 677 - 678
  • [35] Donor cell t(8:21) AML after allogeneic unrelated donor hematopoietic stem cell transplantation for infant ALL
    Sabet, I.
    Vora, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 166 - 166
  • [36] Outcome of matched sibling donor hematopoietic stem cell transplantation for standard risk pediatric acute myelogenous leukemia in first complete remission (CR1)
    Gassas, Adam
    Afzal, Samina
    Ishaqi, M. Kashif
    Dupuis, Annie
    Doyle, John
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 619 - 619
  • [37] Improved survival by allogeneic haematopoietic stem cell transplantation versus autologous HSCT or chemotherapy as consolidation therapy in AML CR1 patients aged 40-60 years: the role of reduced-intensity conditioning and leukaemia risk category
    Cornelissen, J. J.
    Gratwohl, A.
    van Montfort, K. A. G. M.
    Pabst, T.
    Maertens, J.
    Kooy, M. van Marwijk
    Wijermans, P. W.
    Biemond, B. J.
    Breems, D. A.
    Vellenga, E.
    Verdonck, L. F.
    Fey, M.
    Schouten, H.
    Jongen-Lavrencic, M.
    Huls, G. A.
    Janssen, J. J. W. M.
    Kuball, J. H. E.
    Passweg, J. R.
    Graux, C.
    Ossenkoppele, G. J.
    Loewenberg, B.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S76 - S76
  • [38] Allogeneic Stem Cell Transplantation In Adults With High Risk Acute Lymphoblastic Leukemia (ALL) In 1. Remission (CR1): Promising, But Strongly Influenced By ALL Subtypes
    Arnold, Renate
    Terwey, Theis H.
    Giang Lam Vuong
    Ostendorf, Benjamin
    Penack, Olaf
    Massenkeil, Gera
    Goekbuget, Nicola
    Hemmati, Philipp
    BLOOD, 2013, 122 (21)
  • [39] ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
    Jentzsch, Madlen
    Grimm, Juliane
    Bill, Marius
    Brauer, Dominic
    Backhaus, Donata
    Goldmann, Karoline
    Schulz, Julia
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    BONE MARROW TRANSPLANTATION, 2021, 56 (04) : 936 - 945
  • [40] ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
    Madlen Jentzsch
    Juliane Grimm
    Marius Bill
    Dominic Brauer
    Donata Backhaus
    Karoline Goldmann
    Julia Schulz
    Dietger Niederwieser
    Uwe Platzbecker
    Sebastian Schwind
    Bone Marrow Transplantation, 2021, 56 : 936 - 945
12345